Emergent synthetic methods for the modular advancement of sp3-rich fragments Max J. Caplin a and Daniel J. Foley *a Abstract Fragment-based drug discovery is an important and increasingly reliable technology for the delivery of clinical candidates. Notably, however, sp3-rich fragments are a largely untapped resource in molecular discovery, in part due to the lack of general and suitably robust chemical methods available to aid their development into higher affinity lead and drug compounds.